Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Trial of Burosumab (KRN23) in Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome with Post-marketing Extension
jRCT2080223136Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of burosumab in tumor-induced osteomalacia (TIO) and epidermal nevus syndrome (ENS), sponsored by Kyowa Kirin. Started Mar 2016; status: completed.
02
Drugs
burosumab
03
Conditions
tumor-induced osteomalacia (TIO)epidermal nevus syndrome (ENS)
Beyond the preview
Go deeper on jRCT2080223136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223136.